Molecular Docking and In Silico Study of Denileukin Diftitox: Comparison of Wild Type With C519S Mutant
Background: Denileukin diftitox (trade name, Ontak) is the first recombinant immunotoxin (IM), in which the binding domain of diphtheria toxin has been replaced by the amino acid sequence of human interleukin-2 (DT389IL-2) using genetic engineering. Purity, stability, and structural property of the...
Main Authors: | Mohamad Najarasl, Mehdi Zeinoddini, Ali Reza Saeeidinia, Reza Hasan Sajedi |
---|---|
Format: | Article |
Language: | English |
Published: |
Mazandaran University of Medical Sciences and Health Services
2020-05-01
|
Series: | Research in Molecular Medicine |
Subjects: | |
Online Access: | http://rmm.mazums.ac.ir/article-1-346-en.html |
Similar Items
-
Production of Recombinant Denileukin Diftitox: Assessment in the Lab-scale Bioreactor
by: Seyed Morteza Robatjazi, et al.
Published: (2019-08-01) -
Successful Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma with Denileukin Diftitox
by: Mayuko Amagai, et al.
Published: (2022-08-01) -
Advanced-Stage Primary Cutaneous T-Cell Lymphoma Treated with Bexarotene and Denileukin Diftitox
by: Iván Cervigón-González, et al.
Published: (2011-02-01) -
Targeting regulatory T cells by E7777 enhances CD8 T-cell–mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models
by: Haider S. Mahdi, et al.
Published: (2023-10-01) -
Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma
by: Frederick Lansigan, et al.
Published: (2010-02-01)